

Law Offices of
Dieterich & Associates

*11835 W. Olympic Boulevard
Suite 1235E
Los Angeles, California 90064*

*Christopher Dieterich
Of Counsel
Mike Khalilpour
J. John Combs
Bryon Y. Chung*

*(310) 312-6888

FAX (310) 312-6680
venturelaw@gmail.com*

May 8, 2018

OTC Markets Group
304 Hudson Street
Second Floor
New York, NY 10013

RE: *Legal Opinion concerning Adequate Current Information of
Loans4Less.com, Inc. (Symbol – LFLS)*

Ladies/Gentlemen:

You are entitled to rely on this letter in determining whether Loans4Less.com, Inc. (the “Issuer”) has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

I am a resident of the United States and have been retained by the Issuer for the purpose of rendering this letter and related matters. This firm’s relationship with the Issuer includes, over and above writing this letter, serving as special securities counsel for the Issuer, which duties include preparing or reviewing disclosure information and press releases, interfacing with the chief financial officer and independent accountants, and giving general legal advice to management.

I have examined such corporate records and other documents and such questions of law as I have considered necessary or appropriate for purposes of writing this letter. In all such examinations, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as copies and the authenticity of all originals of such documents submitted as copies. Further, in all such examinations, I may have relied on information obtained from public officials, officers of the Issuer, and other sources, and represent that all such sources are believed to be reliable.

This letter relates to the laws of the United States, specifically Federal securities law. I have been a member in good standing of the bar of the State of California since 1980, and am permitted to practice before the Securities and Exchange Commission (the “SEC”) and I have not been prohibited from practice thereunder.

The Issuer is not a reporting company and, therefore, does not file annual or other reports with the SEC. I have reviewed publicly available information relating to the Issuer Including:

- (i) the Issuer's profile posted on the OTC Markets Group website;
- (ii) its Initial Company information and Disclosure Statement filed with the OTC Markets Group on January 7, 2008 (including additional exhibits, Articles of Incorporation, Bylaws, Interim Financial Statement for 3rd Quarter, and Annual Statements for December 31, 2005 and 2006), all unaudited, also filed on January 7, 2008;
- (iii) its unaudited financials statements for the period ended December 31, 2007, filed with the OTC Markets Group on January 27, 2008;
- (iv) its Attorney Letter with Respect to Current Information, filed with the OTC Markets Group on March 10, 2008 and updated on May 20, 2008;
- (v) its unaudited interim Quarterly Reports for the first, second and third quarters of the year ended December 31, 2008, filed with the OTC Markets Group on May, 20, 2008, August 15, 2008 and November 18, 2008, respectively;
- (vi) its unaudited Annual Report for the year ended December 31, 2008, filed with the OTC Markets Group on February 9, 2009, and updated on March 24, 2009, along with its companion Attorney Letter with Respect to Current Information, filed March 31, 2009;
- (vii) its unaudited interim Quarterly Reports for the first, second and third quarters of 2009, filed with the OTC Markets Group on May 7, 2009, July 20, 2009 and October 2009, respectively, along with companion Attorney Letters with Respect to Current Information filed on May 26, 2009 and October 20, 2009;
- (viii) its Annual Report for the year ended December 31, 2009, and the Annual Report Supplemental Information, filed with the OTC Markets Group on January 18, 2010 and March 17, 2010, respectively, and the supporting Attorney Letter with Respect to Current Information, filed on March 30, 2010;
- (ix) its unaudited interim Quarterly Reports, for the first, second and third quarters of 2010, filed with OTC Markets Group on May 4, 2010, July 13, 2010;
- (x) its unaudited Annual Report for the year ended December 31, 2010, and the Annual Report - Supplemental Information, filed with OTC Markets Group on February 8, 2011 and March 29, 2011, respectively, along with the Attorney Letter with Respect to Current Information filed on April 8, 2011;
- (xi) its unaudited interim Quarterly Reports for the first, second and third quarters of 2011, filed with OTC Markets Group on May 9, July 25, and October 27, 2010, respectively;
- (xii) its unaudited Annual Report for the year ended December 31, 2011, filed with OTC Markets Group on February 21, 2012, and then refiled in a revised format on August 5, 2012;
- (xiii) the unaudited Quarterly Report for March 31, 2012, filed with OTC Markets Group on May 14, 2012;
- (xiv) the unaudited Quarterly Report for June 30, 2012, filed with OTC Markets Group on August 5, 2012;
- (xv) the unaudited Quarterly Report for September 30, 2012, filed with OTC Markets Group on November 5, 2012;
- (xvi) its audited Annual Report for the year ended December 31, 2012, filed with OTC Markets Group on March 15, 2013;
- (xvii) its unaudited Quarterly Report for March 31, 2013, filed with OTC Markets Group on May 3, 2013 and as updated on May 6, 2013;
- (xviii) its unaudited Quarterly Report for June 30, 2013, filed with OTC Markets Group on July 24, 2013;

(xviii) its unaudited Quarterly Report for September 30, 2013, filed with OTC Markets Group on November 5, 2013;

(xix) its unaudited Annual Report for December 31, 2013, filed with OTC Markets Group on February 12, 2014;

(xx) its unaudited Quarterly Report for March 31, 2014, filed with OTC Markets Group on May 5, 2014;

(xxi) its unaudited Quarterly Report for June 30, 2014, filed with OTC Markets Group on August 12, 2014;

(xxii) its unaudited Quarterly Report for September 30, 2014, filed with OTC Markets Group on November 12, 2014;

(xxiii) its unaudited Annual Report for the year ended December 31, 2014, and accompanying Audited Financial Statements (for fiscal 2014 and 2013), both filed with OTC Markets Group on February 12, 2015;

(xxiv) its Quarterly Report for March 31, 2015, filed with OTC Markets Group on July 3, 2015;

(xxv) its Quarterly Report for June 30, 2015, filed with OTC Markets Group on August 13, 2015;

(xxvi) its Quarterly Report for September 30, 2015, filed with OTC Markets Group on November 16, 2015;

(xxvii) its Annual Report for the year ended December 31, 2015, filed with OTC Markets Group on June 6, 2016;

(xxviii) its Quarterly Reports for March 31, 2016, June 30, 2016 and September 30, 2016, filed with OTC Markets Group on July 1, September 30 and November 14, 2016, respectively;

(xxix) its Annual Report for the year ended December 31, 2016, filed with OTC Markets Group on June 7, 2017;

(xxx) its Quarterly Reports for March 31, June 30 and September 30, 2017, filed with OTC Markets Group on June 15, August 16 and November 10, 2017, respectively; and

(xxxi) its Annual Report for the year ended December 31, 2017, filed with OTC Markets Group on March 15, 2018.

All of the above reports constitute the "Information" available to the public. The Company's financial statements provided in the Information have not been audited until 2013, at which point they were audited for the entirety of 2013 and 2014. The 2015, 2016 and 2017 statements have not been audited.

It is my opinion that the Information (i) constitutes adequate current public information concerning the Issuer's securities and it is available within the meaning of Rule 144(c)(2) under the Securities Act of 1933; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iii) complies as to form with the OTC Markets Group's Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com; and (iv) has been posted through the OTC Disclosure and News Service.

The person responsible for the preparation and compilation of the financial statements contained in the Information is Steven M. Hershman. Mr. Hershman is qualified to compile and certify the financial statements because of his over 26 years in the financial services industry, both in the United States and England, where he was a Member of the London Stock Exchange and also held securities licenses in the United States from 1982 through 1989, while working with US-

based brokerages. The financial statements are generally prepared by staff personnel, delivered to an assembly person, and then, as necessary, reviewed by Marc Phelps, CPA as to any material changes to operations or presentation, and then approved and certified by Mr. Hershman.

The Issuer's transfer agent is Transfer Online, Inc., which is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information was to contact the Issuer's transfer agent and receive confirmation as to the number of outstanding shares. As of March 31, 2018, the total number of outstanding shares of common stock of the Issuer was 56,870,480.

I have personally met with management and a majority of the directors of the Issuer. I have reviewed the Information published by the Issuer through the OTC Disclosure and News Service. I have discussed the Information with management and a majority of the directors of the Issuer.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither, counsel nor any officer, director or 5% holder of the securities of the Issuer is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

No person other than the OTC Markets Group is entitled to rely on this letter. However, I hereby grant the OTC Markets Group full and complete permission and rights to publish the letter through the OTC Disclosure and New Service for viewing by the public and regulators.

I have compiled a list below, as of about May 7, 2018, of the names of each executive officer, director, other control persons of the Issuer, consultant or any other advisor of the Issuer who assisted, prepared or provided information with respect to the Issuer's disclosure or who received securities as consideration for services rendered to the Issuer and the following information related to each: (i) their full name, (ii) their business address, (iii) the number and class of the Issuer's securities beneficially owned by each of them (iv) with respect to each of the securities described in the preceding clause whether or not the certificate or other document that evidences the securities contains a legend stating that the securities have not been registered under the Securities Act and setting forth the referring to restrictions on transferability and sale of the securities and (v) a complete description of the consideration received by the Issuer in connection with each issuance of shares to any of them including, without limitation, the nature of any services performed for or on behalf of the Issuer. For purpose of this letter, the term "control person" includes (i) any person controlling, under common control with, or controlled by, the Issuer or (ii) any person who obtained securities of the Issuer in connection with a negotiation with the Issuer within the three-year period prior to the date of the opinion. With respect to any of the Issuer's control persons that is an entity and any parent entity of any control person, this letter provides the information described in the first sentence of this paragraph for each control person of such entity or parent entity.


- (I) **Name: Steven M. Hershman**
President, CEO, Treasurer, Chief Financial Officer and Chairman of the Board
 - (ii) Business Address: 22409 Susana Avenue, Torrance, CA 90505
 - (iii) Number and Class of Shares Beneficially Owned: As of December 31, 2017
22,841,005 Common Shares and 21,500,000 Series A Preferred Stock.
 - (iv) Shares are restricted.
 - (v) Acquired shares exchanged for asset contribution at company formation (25,000,000 common and 21,500,000 Series A Preferred Stock) and the remainder, subsequently, for services rendered.
-
- (I) **Name: Daniela Haynie**, Executive Vice President, General Manager, Director
 - (ii) Business Address: 22409 Susana Avenue, Torrance, CA 90505
 - (iii) Number and Class of Shares Beneficially Owned: 2,257,000 Common Shares (includes 2,000 shares of common stock owned by her husband, Jack Haynie)
 - (iv) Shares are restricted
 - (v) Acquired shares for services rendered
-
- (i) **Name: Marc Charles Phelps**, CPA, Director/Consultant
 - (ii) Business Address: 222 N. Sepulveda Blvd., Suite 2000, El Segundo, CA 90245
 - (iii) Number and Class of Shares Beneficially Owned: 350,000 Common Shares
 - (iv) Shares are restricted
 - (v) Acquired shares for services rendered

I have made specific inquiry of each of the persons listed above, persons engaged in promotional activities regarding the Issuer, and persons owning more than ten percent (10%) of the Securities (collectively, the "Insiders"), and based upon such inquiries and other information available to counsel, there were no sales of shares, but there were redemptions. From January 1, 2015 through December 31, 2015, 448,500 common shares were redeemed by the company from Steven M. Hershman, and from January 1, 2016 through December 31, 2016, an additional 1,062,317 shares were redeemed by the company from Steven M. Hershman, and from January 1, 2017 through December 31, 2017, an additional 335,000 shares were redeemed by the company from Steven M. Hershman: Not one of these shares was sold into the open marketplace. Nothing has come to the attention of counsel indicating that any Insider is in possession of any material non-public information regarding the Issuer of the Securities that would prohibit any of them from buying or selling the Securities under Rules 10b-5 or 10b5-1 under the Exchange Act.

I trust this information complies with your request. If you need additional information please contact me.

Very truly yours,

DIETERICH & ASSOCIATES


Signed: Christopher Dieterich